Financial Reports Latest Updates Industry Maps Economic Calendar

Lunai Bioworks Inc. (LNAI) Annual Reports

Q: Where can I read Lunai Bioworks Inc. (LNAI) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Lunai Bioworks Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 06/30
SEC CIK： 1527728 →

Website：Official site ↗

Financial Highlights

FY2026 Q3 (quarterly, ended 2026-03-31)
	Current	Prior year	YoY
Revenue	$20,942	—	—
Operating income	$-1.5M	$-4.2M	+64.5%
Net income	$-2.6M	$189,176	-1459.3%
EPS (diluted)	$-0.10	$0.00	—

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0.02 mn Net income -2.57 mn

Periods follow the company’s fiscal year (Apple ends in September, Walmart in January), so they differ from calendar quarters.

Show table：Income statement

Item	2011Q1	2011Q2	2011Q3	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2016Q1	2016Q1	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Revenue	0	—	—	—	0	—	—	0.06	0.03	0	0	0	—	—	—	0	—	—	—	0.04	0.04	0	—	—	—	—	—	—	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.02
Gross profit	—	—	—	—	—	—	—	0	0.02	-0.04	-0.02	-0.04	-0.02	-0.06	-0.14	-0.07	-0.04	-0.02	—	0.04	0.04	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.02
Operating income	—	—	-0.01	-0.01	—	—	—	-1.92	-0.18	-0.24	-0.34	-0.98	-0.41	-0.57	-0.51	-0.94	-0.87	-1.87	-0.34	-0.59	-0.51	-0.67	-0.85	-0.55	-0.35	-0.9	-0.63	-1.28	-3.24	-3.02	-3.77	-6.27	-4.66	3.70	-2.44	-2.82	-3.83	-2.83	-2.86	-3.31	-3.05	-14.2	-7.50	-6.33	-4.03	-98.2	-7.19	-4.37	-4.06	-22.9	-8.88	-4.27	-17.2	-51.3	-53.3	-4.55	-4.16	-127	-3.31	-1.82	-1.48
Net income	-0.01	0	-0.01	-0.01	0	-0.01	-0.01	-0.01	-0.4	0	-0.02	-0.01	-0.43	-0.47	-0.54	-0.95	-1.25	-1.42	-0.35	-0.42	-0.21	-0.76	-0.79	-0.92	-0.25	-0.43	-0.23	-1.08	0.02	-0.01	-2.30	-18.0	-4.71	6.98	-4.08	-1.72	-1.51	-4.10	-2.40	-2.93	-4.03	-17.4	-10.4	-6.58	-6.20	-90.2	-7.70	-4.46	-4.33	-23.2	-9.18	-4.53	-17.0	-49.9	-44.2	-7.25	0.19	-127	2.82	-1.80	-2.57

Balance sheet

Quarterly · In mn (USD)

Total assets 9.86 mn Total liabilities 19.4 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011Q1	2011Q2	2011Q3	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2016Q1	2016Q1	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Current assets	0	—	0.02	0.01	0.01	0.01	0.02	0.01	0.02	0.01	0.01	0	0.56	0.42	2.35	5.05	3.48	1.91	1.57	1.19	0.84	0.73	0.78	0.28	0.23	4.20	3.16	7.24	17.1	15.8	13.6	13.3	10.5	12.5	11.2	9.06	11.3	8.94	6.07	4.01	4.92	20.9	15.5	14.6	11.7	9.57	8.13	5.39	3.93	2.57	1.91	2.40	1.22	2.00	1.95	1.71	3.67	1.05	0.8	0.51	3.73
Total assets	0	—	0.02	0.01	0.01	0.01	0.02	0.01	0.02	0.01	0.01	0	0.91	0.72	2.55	5.24	3.64	2.07	1.73	1.34	0.98	0.87	0.94	0.43	0.38	4.52	3.71	7.83	144	180	176	174	169	180	181	178	181	178	175	173	174	190	184	183	180	84.6	83.1	80.3	78.7	58.3	57.6	58.0	212	163	122	111	118	8.23	6.96	6.67	9.86
Current liabilities	0.01	—	0.02	0.02	0.03	0.04	0.05	0.05	0.07	0.07	0.08	0.08	3.10	3.35	4.93	1.76	0.97	1.00	1.01	0.89	1.04	1.51	1.41	1.41	1.99	2.99	0.95	5.97	0.91	0.87	0.78	1.64	1.52	1.11	1.30	1.09	0.97	1.33	0.83	1.56	1.41	1.89	1.21	6.20	7.51	6.45	7.16	11.3	11.8	11.0	10.1	13.8	20.9	30.3	23.0	28.6	28.8	29.2	19.7	20.0	19.3
Total liabilities	—	—	—	—	—	—	—	4.73	—	—	—	2.13	3.10	3.35	4.93	1.76	0.97	1.00	1.01	0.89	1.04	1.51	1.74	1.72	1.99	2.99	0.95	5.97	0.91	23.8	22.2	25.2	25.3	6.78	8.44	7.08	10.3	11.8	10.9	10.9	11.4	14.9	—	17.5	18.9	12.0	12.8	13.4	12.6	11.8	10.8	14.4	43.7	31.1	23.8	29.3	29.3	29.6	20.0	20.2	19.4
Equity	-0.01	—	0	-0.01	-0.01	-0.02	-0.03	-0.04	-0.05	-0.05	-0.07	-0.08	-2.35	-2.63	-2.38	3.48	2.67	1.08	0.72	0.44	-0.06	-0.64	-0.8	-1.28	-1.61	1.53	2.76	1.85	143	156	154	149	144	173	172	171	170	166	164	162	162	175	167	166	161	72.6	70.3	66.9	66.1	46.5	46.8	43.6	169	132	98.1	82.1	88.4	-21.4	-13.0	-13.6	-9.55

Cash flow

Quarterly · In mn (USD)

Operating -1.03 mn Investing 0 mn Financing 3.70 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011Q1	2011Q2	2011Q3	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2016Q1	2016Q1	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Operating	0	0	0	-0.01	0	-0.01	-0.01	-0.93	-1.12	-0.01	-0.01	-0.02	-0.44	-0.2	-0.48	-0.93	-2.04	-1.79	-0.42	-0.67	-1.16	-0.31	-0.33	-0.32	-0.68	-0.5	-0.51	-0.49	-1.73	-1.61	-1.80	-1.75	-2.73	-2.23	-1.80	-2.58	-3.84	-2.25	-2.76	-2.50	-2.33	-13.0	-5.28	-4.62	-2.78	-3.05	-2.82	-3.38	-3.31	-2.26	-2.78	-3.15	-2.63	-2.41	-2.02	-2.56	-1.49	-1.81	-1.35	-1.07	-1.03
Investing	0	—	-0.01	0	0	0	0	-0.08	0	-0.01	0	0.01	-0.4	0.33	0.13	-2.01	2.03	-1.05	1.05	0	1.05	0	—	—	—	-0.2	-0.23	-4.84	4.78	-0.3	-0.31	-0.33	-0.09	0.02	-0.07	-0.06	-0.04	-0.01	0	-0.01	0	-0.04	-0.01	0	0	0	—	-0.02	0	-0.01	-1.06	-0.06	-0.09	-0.05	0	—	-1.46	0.96	0.54	0	0
Financing	0	0.01	0.03	0	0.01	0.01	0.01	0.86	0.99	0	0.01	0	0.87	-0.01	0.53	5.28	0	—	—	—	—	—	0.36	0	0.41	5.09	0	4.82	11.9	0	—	1.70	0	4.32	1.00	0	6.20	0	0	-0.04	3.44	29.2	0	2.95	0.23	1.07	1.63	-0.47	2.11	1.25	2.56	2.85	2.64	2.47	2.03	2.59	3.58	0.18	1.34	0.95	3.70
Cash at period end	—	—	—	—	—	—	—	0	—	—	—	0.02	0.05	0.18	0.6	3.01	3.43	0.42	1.05	0.53	0.15	0.02	0.03	0.12	0.03	3.94	2.94	2.31	17.0	15.6	13.4	13.2	10.3	12.3	11.1	8.63	10.9	8.70	5.97	3.43	4.53	20.7	15.4	13.7	11.2	9.17	7.97	4.12	2.95	1.87	0.52	0.24	0.31	0.22	0.22	0.31	0.92	0.09	0.62	0.49	3.16

Profitability

Quarterly · %

Gross margin 100.0% Operating margin -7054.1% Net margin -12278.6%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2011Q1	2011Q2	2011Q3	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2016Q1	2016Q1	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Gross margin	—	—	—	—	—	—	—	-2.5%	51.3%	—	-1651.1%	-14220.4%	—	—	—	—	—	—	—	87.7%	87.7%	87.3%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	100.0%
Operating margin	—	—	—	—	—	—	—	-3063.4%	-571.9%	—	-36676.9%	-342600.3%	—	—	—	—	—	—	—	-1399.0%	-1207.8%	-274996.3%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-7054.1%
Net margin	—	—	—	—	—	—	—	-15.6%	-1264.6%	—	-1772.5%	-3033.3%	—	—	—	—	—	—	—	-991.8%	-488.1%	-309671.3%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-12278.6%

Returns & leverage

Quarterly · %

ROE -325.5% ROA -201.1% Debt ratio 196.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2011Q1	2011Q2	2011Q3	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2016Q1	2016Q1	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-140.1%	-1983.0%	—	—	-175.6%	-184.0%	-789.2%	—	—	—	-534.5%	-186.1%	-697.7%	-2.4%	-1.6%	-4.3%	-27.0%	-17.4%	-10.9%	-12.2%	-2.2%	-0.2%	-6.7%	-5.8%	-6.6%	-8.1%	-15.7%	-21.0%	-23.4%	-25.1%	-91.7%	-93.3%	-93.4%	-93.9%	-66.6%	-70.3%	-74.6%	-46.0%	-90.4%	-159.8%	-188.5%	-78.8%	-321.8%	-308.0%	-366.4%	-325.5%
ROA	—	—	—	-256.9%	-441.8%	-301.8%	-185.8%	-241.7%	-2547.6%	-3103.5%	-2980.4%	-6374.0%	-97.5%	-251.6%	-112.2%	-91.0%	-141.0%	-298.2%	-185.7%	-104.8%	-103.8%	-117.9%	-162.8%	-302.8%	-398.2%	-88.7%	-78.4%	-48.0%	-2.4%	-1.4%	-3.8%	-22.3%	-16.0%	-10.0%	-11.1%	-2.0%	-0.2%	-6.4%	-5.5%	-6.2%	-7.6%	-14.5%	-19.3%	-21.6%	-22.9%	-82.7%	-82.9%	-82.5%	-82.5%	-55.5%	-58.5%	-59.6%	-37.1%	-72.8%	-129.0%	-139.8%	-61.3%	-207.8%	-203.4%	-212.7%	-201.1%
Debt ratio	—	—	—	—	—	—	—	35364.4%	—	—	—	9702895.4%	339.8%	466.3%	193.3%	33.5%	26.7%	48.0%	58.6%	66.9%	106.5%	173.2%	184.5%	398.0%	520.1%	66.1%	25.6%	76.3%	0.6%	13.2%	12.6%	14.5%	15.0%	3.8%	4.7%	4.0%	5.7%	6.6%	6.2%	6.3%	6.5%	7.9%	—	9.6%	10.5%	14.2%	15.3%	16.7%	16.0%	20.2%	18.8%	24.9%	20.6%	19.1%	19.5%	26.3%	24.9%	359.4%	287.4%	303.2%	196.9%

EPS

Quarterly · US$

EPS US$-0.10

Show table：EPS

Item	2011Q1	2011Q2	2011Q3	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2016Q1	2016Q1	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2.16	-0.14	-0.08	-0.08	-0.41	-0.14	-0.07	-0.16	-0.45	-0.28	-0.04	0.00	-0.76	0.13	-0.08	-0.10

Revenue & profit

Year-to-date · In mn (USD)

Revenue 0.03 mn Net income -1.55 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 9.86 mn Total liabilities 19.4 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -3.45 mn Investing 0.54 mn Financing 6.00 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Gross margin -233.6% Operating margin -5306.9% Net margin -1303.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -325.5% ROA -201.1% Debt ratio 196.9%

EPS

Year-to-date · US$

EPS US$-0.05

Revenue & profit

Annual · In mn (USD)

Net income -178 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2011	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Gross profit	—	-0.3	—	—	—	—	—	—	—	—	—	—
Operating income	—	-2.43	-4.86	-2.65	-8.17	-11.0	-11.9	-23.4	-116	-38.6	-81.6	-189
Net income	-0.03	-2.38	-4.41	-2.39	-1.30	-18.0	-11.4	-26.7	-113	-39.7	-80.7	-178

Balance sheet

Annual · In mn (USD)

Total assets 8.23 mn Total liabilities 29.6 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	0.01	5.05	0.73	4.20	15.8	12.5	8.94	20.9	9.57	2.57	2.00	1.05
Total assets	0.01	5.24	0.87	4.52	180	180	178	190	84.6	58.3	163	8.23
Current liabilities	0.02	1.76	1.51	2.99	0.87	1.11	1.33	1.89	6.45	11.0	30.3	29.2
Total liabilities	—	1.76	1.51	2.99	23.8	6.78	11.8	14.9	12.0	11.8	31.1	29.6
Equity	-0.01	3.48	-0.64	1.53	156	173	166	175	72.6	46.5	132	-21.4

Cash flow

Annual · In mn (USD)

Operating -7.87 mn Investing -1.26 mn Financing 8.38 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-0.02	-2.05	-6.39	-1.83	-4.34	-8.51	-10.5	-20.6	-15.7	-11.8	-11.0	-7.87
Investing	—	-1.95	3.08	—	-0.58	-0.72	-0.18	-0.05	-0.01	—	-1.26	—
Financing	0.03	6.67	—	5.87	16.7	—	7.20	32.6	4.25	4.52	10.5	8.38
Cash at period end	—	3.01	0.02	3.94	15.6	12.3	8.70	20.7	9.17	1.87	0.22	0.09

Returns & leverage

Annual · %

ROE -321.8% ROA -207.8% Debt ratio 359.4%

Show table：Returns & leverage

Item	2011	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-137.3%	-309.9%	-534.5%	-1.6%	-10.9%	-6.7%	-15.7%	-91.7%	-66.6%	-90.4%	-321.8%
ROA	-256.9%	-90.8%	-144.3%	-88.7%	-1.4%	-10.0%	-6.4%	-14.5%	-82.7%	-55.5%	-72.8%	-207.8%
Debt ratio	—	33.5%	173.2%	66.1%	13.2%	3.8%	6.6%	7.9%	14.2%	20.2%	19.1%	359.4%

EPS

Annual · US$

EPS US$-1.08

Show table：EPS

Item	2011	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	—	—	-0.71	-0.82	-1.08

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Lunai Bioworks Inc. (LNAI) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.